Baseline characteristics of study participants
| . | Early HIV . | Chronic HIV . | HIV-negative . |
|---|---|---|---|
| Number of participants | 43 | 50 | 35 |
| Age, y* | 36 (19-61) | 34 (20-58) | 36 (22-44) |
| Male sex (%) | 100 | 100 | 100 |
| CD4+ T-cell count (cells/μL)* | 486 (150-873) | 272 (33-924) | 924 (486-1470) |
| CD8+ T-cell count (cells/μL)* | 851 (329-3421) | 851 (209-1672) | 518 (239-1103) |
| CD19+ B-cell count (cells/μL)* | 136 (38-398) | 145 (33-686) | 277 (114-671) |
| HIV RNA (copies/mL plasma)† | 69 551 (1681-2 436 000) | 56 328 (3361-1 823 000) | N/A |
| . | Early HIV . | Chronic HIV . | HIV-negative . |
|---|---|---|---|
| Number of participants | 43 | 50 | 35 |
| Age, y* | 36 (19-61) | 34 (20-58) | 36 (22-44) |
| Male sex (%) | 100 | 100 | 100 |
| CD4+ T-cell count (cells/μL)* | 486 (150-873) | 272 (33-924) | 924 (486-1470) |
| CD8+ T-cell count (cells/μL)* | 851 (329-3421) | 851 (209-1672) | 518 (239-1103) |
| CD19+ B-cell count (cells/μL)* | 136 (38-398) | 145 (33-686) | 277 (114-671) |
| HIV RNA (copies/mL plasma)† | 69 551 (1681-2 436 000) | 56 328 (3361-1 823 000) | N/A |